Allergan Botox increase could provide incremental upside, says Credit Suisse Credit Suisse said Allergan's first price in six years for Botox could lead to incremental upside to Street estimates. The firm expects 2014 guidance to be a catalyst for shares and raised estimates and price target to $123 from $112. Shares are Outperform rated.
Actavis completes acquisition of Allergan Actavis plc (ACT) announced that it has completed the acquisition of Allergan (AGN) in a cash and equity transaction valued at approximately $70.5B. The combination creates one of the world’s top 10 pharmaceutical companies by sales revenue, with combined annual pro forma revenues of more than $23B anticipated in 2015. Actavis continues to expect the transaction to generate double-digit accretion to non-GAAP earnings within the first 12 months, including approximately $1.8B in operating and financial synergies to be realized within one year following the close. These synergies exclude any additional revenue or manufacturing synergies, and are in addition to the $475M of annual savings previously announced by Allergan in connection with Project Endurance. Actavis further expects to generate strong operating cash flow in excess of $8B in 2016, which would enable the company to rapidly de-lever the balance sheet.